GlassScriptPhysician profile
Ravi S Mehta
NPI 1669462230
$14,067.91
in general payments reported to CMS, 2019-2025
45 companies · $1,269 in 2025
The $1,269 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,720 · 2020: $1,580 · 2021: $944 · 2022: $1,632 · 2023: $1,169 · 2024: $1,753 · 2025: $1,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,144 · Education: $46.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,144.48 |
| Education | $46.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,834.51 | 2019-2025 | Watchman Flx, Watchman Access System, Bodyguardian |
| Edwards Lifesciences Corporation | $1,625.30 | 2019-2020 | |
| Medtronic Vascular, INC. | $1,621.54 | 2019 | |
| Shockwave Medical, INC | $1,019.09 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abbott Laboratories | $929.80 | 2019-2025 | Ultreon, Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $866.28 | 2019-2025 | Lifevest |
| Nuwellis, INC. | $858.19 | 2020 | |
| Novartis Pharmaceuticals Corporation | $644.27 | 2019-2025 | |
| Abiomed | $592.99 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $531.04 | 2019-2023 | Uptravi, Opsumit |
| Heartflow, INC. | $458.31 | 2023-2025 | Ffrct |
| Inari Medical, INC. | $443.55 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Pharmaceuticals, INC | $365.01 | 2019-2023 | Xarelto |
| Atricure, INC. | $305.34 | 2024 | |
| Amgen INC. | $221.78 | 2019-2025 | Repatha, Repatha |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.